6
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      IDH2 Mutations Define a Unique Subtype of Breast Cancer with Altered Nuclear Polarity

      research-article
      1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 2 , 2 , 3 , 4 , 2 , 5 , 6 , 7 , 8 , 9 , 10 , 1 , 11 , 12 , 13 , 14 , 1 , 10 , 6 , 15 , 1 , 15 , 16
      Cancer research
      IDH2 mutation , PIK3CA mutation , PIK3 pathway, breast cancer, nuclear polarity

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Solid papillary carcinoma with reverse polarity (SPCRP) is a rare breast cancer subtype with an obscure etiology. In this study, we sought to describe its unique histopathologic features and to identify the genetic alterations that underpin SPCRP using massively parallel whole-exome and targeted sequencing. The morphologic and immunohistochemical features of SPCRP support the invasive nature of this subtype. Ten of 13 (77%) SPCRPs harbored hotspot mutations at R172 of the isocitrate dehydrogenase IDH2, of which 8 of 10 displayed concurrent pathogenic mutations affecting PIK3CA or PIK3R1. One of the IDH2 wild-type SPCRPs harbored a TET2 Q548* truncating mutation coupled with a PIK3CA H1047R mutation. Functional studies demonstrated that IDH2 and PIK3CA hotspot mutations are likely drivers of SPCRP, resulting in its reversed nuclear polarization phenotype. Our results offer a molecular definition of SPCRP as a distinct breast cancer subtype. Concurrent IDH2 and PIK3CA mutations may help diagnose SPCRP and possibly direct effective treatment.

          Related collections

          Author and article information

          Journal
          2984705R
          2786
          Cancer Res
          Cancer Res.
          Cancer research
          0008-5472
          1538-7445
          25 February 2017
          20 October 2016
          15 December 2016
          15 December 2017
          : 76
          : 24
          : 7118-7129
          Affiliations
          [1 ]Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
          [2 ]German Consortium of Translational Cancer Research (DKTK), Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), INF 280, Heidelberg, Germany
          [3 ]Department of Pathology, University of Chicago, Chicago, IL, USA
          [4 ]Department of Pathology, University of Iowa Hospital and Clinics, Iowa City, IA, USA
          [5 ]Department of Neuropathology, Institute of Pathology, INF 224, Ruprecht-Karls-University Heidelberg, Heidelberg, Germany
          [6 ]Department of Pathology, Massachusetts General Hospital, Boston, MA, USA
          [7 ]Department of Pathology, Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA
          [8 ]Pathology North, North Shore Private Hospital, New South Wales, Australia
          [9 ]Miami Valley Hospital, Dayton, OH, USA
          [10 ]Department of Pathology, New York University Langone Medical Center and Medical School, New York, NY, USA
          [11 ]Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
          [12 ]Department of Pathology, Mon General Hospital, Morgantown, WV, USA
          [13 ]ABQ Health Partners, Albuquerque, NM, USA
          [14 ]Maine Medical Center, Portland, ME, USA
          [15 ]Department of Pathology, Harvard Medical School, Boston, MA, USA
          [16 ]Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA, USA
          Author notes
          []Corresponding author: Department of Pathology, Beth Israel Deaconess Medical Center, 330 Brookline Ave, Boston, MA 02215, Phone: 617-667-4344, Fax: 617-975-5620, sschnitt@ 123456bidmc.harvard.edu
          [*]

          Equal contribution

          [§]

          Current address: Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA

          Article
          PMC5502804 PMC5502804 5502804 nihpa826990
          10.1158/0008-5472.CAN-16-0298
          5502804
          27913435
          529098cf-c624-4be1-8ca0-60615154f33c
          History
          Categories
          Article

          PIK3CA mutation, IDH2 mutation,PIK3 pathway,breast cancer,nuclear polarity

          Comments

          Comment on this article